Presentations by Event

Presented at ECCMID, Amsterdam, April 2019

Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Target Attainment Analyses of ETX2514SUL to Support Dosing Regimens in Patients with Varying Renal Function

N.J. Onufrak (ICPD), ECCMID 2019

Program(s): etx2514

Efficacy of Cefpodoxime proxetil and ETX0282 in a murine UTI model with E. coli and K. pneumoniae

W.J. Weiss (UNTHSC), ECCMID 2019

Program(s): etx0282

The Susceptibility of Sulbactam/ETX2514 and Comparators to Global Isolates of Acinetobacter baumannii

Harald Seifert (University of Cologne), ECCMID 2019

Program(s): etx2514

Restoration of Sulbactam Activity by the Novel β-lactamase Inhibitor ETX2514 Against Recent Global Clinical Isolates of Acinetobacter baumanniicalcoaceticusComplex Isolates

Sarah McLeod, ECCMID 2019

Program(s): etx2514

A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis

Suba Srinivasan, ECCMID 2019

Program(s): etx2514

Discovery of a novel series of Penicillin-Binding Protein 3 inhibitors as monotherapy for Pseudomonas aeruginosa infections: Rational design of biochemical potency and bacterial permeation

Thomas Durand-Reville, ECCMID 2019

The Novel β-lactamase Inhibitor ETX1317 Effectively Restores the Activity of Cefpodoxime Against Recent Global EnterobacteriaceaeIsolates from Urinary Tract Infections

Sarah McLeod, ECCMID 2019

Program(s): etx0282

Presented at ID Week, San Francisco, October 2018

EXT2514SUL (sulbactam/ETX2514) For The Treatment of Acinetobactor Baumannii Infections

Robin Isaacs, ID Week 2018

Program(s): etx2514